{"id":8556,"date":"2025-09-11T11:26:58","date_gmt":"2025-09-11T08:26:58","guid":{"rendered":"https:\/\/jordan-cardiac.org\/?p=8556"},"modified":"2025-09-11T11:26:58","modified_gmt":"2025-09-11T08:26:58","slug":"cardiovascular-disease-and-hypertension-in-pregnancy-2025-esc-guidance","status":"publish","type":"post","link":"https:\/\/jordan-cardiac.org\/en\/cardiovascular-disease-and-hypertension-in-pregnancy-2025-esc-guidance\/","title":{"rendered":"Cardiovascular Disease and Hypertension in Pregnancy \u2013 2025 ESC Guidance"},"content":{"rendered":"
Cardiovascular Disease and Hypertension in Pregnancy \u2013 2025 ESC Guidance<\/div>\n
<\/div>\n
Source: 2025 ESC Guidelines on Cardiovascular Disease and Pregnancy; ESC Focused Updates on Hypertension in Pregnancy<\/div>\n
<\/div>\n
1. Shift in Philosophy<\/div>\n
\u2022 The new 2025 ESC guidelines no longer advise all high-risk women to \u201cavoid pregnancy\u201d categorically.<\/span><\/div>\n
\u2022 Instead, emphasis is on personalized, multidisciplinary care with Pregnancy Heart Teams (cardiologists, obstetricians, anesthesiologists, geneticists, and mental health specialists).<\/span><\/div>\n
\u2022 Women\u2019s autonomy is highlighted, ensuring shared decision-making and tailored counseling.<\/span><\/div>\n
<\/div>\n
2. Safe and Commonly Used Medications in Pregnancy<\/div>\n
\u2022 Antihypertensives:<\/span><\/div>\n
\u2022 Labetalol (oral or IV).<\/span><\/div>\n
\u2022 Methyldopa.<\/span><\/div>\n
\u2022 Nifedipine (extended release).<\/span><\/div>\n
\u2022 Other key drugs:<\/span><\/div>\n
\u2022 Low-dose aspirin \u2192 for preeclampsia prevention in high-risk women.<\/span><\/div>\n
\u2022 Heparins (LMWH, UFH) \u2192 preferred anticoagulants during pregnancy.<\/span><\/div>\n
<\/div>\n
3. Second- to Fifth-Line Antihypertensives<\/div>\n
\u2022 Second-line:<\/span><\/div>\n
\u2022 Hydralazine (oral or IV), particularly in severe hypertension.<\/span><\/div>\n
\u2022 Third-line:<\/span><\/div>\n
\u2022 Other calcium channel blockers (e.g., amlodipine) \u2013 safety data growing.<\/span><\/div>\n
\u2022 Beta-blockers other than labetalol (e.g., metoprolol, propranolol) \u2013 generally safe.<\/span><\/div>\n
\u2022 Avoid atenolol (risk of fetal growth restriction).<\/span><\/div>\n
\u2022 Fourth-line (specialist use, case-by-case):<\/span><\/div>\n
\u2022 Clonidine \u2013 limited evidence, more side effects.<\/span><\/div>\n
\u2022 Thiazide diuretics \u2013 may be continued if pre-pregnancy use, but not first choice.<\/span><\/div>\n
\u2022 Fifth-line \/ Rescue therapies (life-threatening only):<\/span><\/div>\n
\u2022 IV nitroglycerin (e.g., pulmonary edema in preeclampsia).<\/span><\/div>\n
\u2022 Sodium nitroprusside \u2013 only for very short duration (risk of cyanide toxicity).<\/span><\/div>\n
<\/div>\n
4. Contraindicated in Pregnancy<\/div>\n
\u2022 Teratogenic agents:<\/span><\/div>\n
\u2022 ACE inhibitors, ARBs, ARNIs, direct renin inhibitors.<\/span><\/div>\n
\u2022 Hormonal\/anti-androgenic risks:<\/span><\/div>\n
\u2022 Spironolactone, eplerenone.<\/span><\/div>\n
\u2022 Beta-blocker specific:<\/span><\/div>\n
\u2022 Atenolol \u2192 linked to fetal growth restriction.<\/span><\/div>\n
\u2022 Lipid therapies:<\/span><\/div>\n
\u2022 Statins generally avoided (though data evolving).<\/span><\/div>\n
\u2022 Anticoagulants:<\/span><\/div>\n
\u2022 Warfarin \u2192 risk of embryopathy (except selected mechanical valve cases with risk-benefit discussion).<\/span><\/div>\n
<\/div>\n
5. Special Notes from ESC 2025<\/div>\n
\u2022 Heart transplantation: Postpone pregnancy for \u22651 year after transplant.<\/span><\/div>\n
\u2022 Cesarean section: Considered in select high-risk cardiovascular cases.<\/span><\/div>\n
\u2022 Case-by-case therapies: Certain lipid and cardiogenetic drugs may be considered under specialist guidance.<\/span><\/div>\n
<\/div>\n
<\/div>\n
https:\/\/www.escardio.org\/Guidelines\/Clinical-Practice-Guidelines\/CVD-and-Pregnancy?utm_source=chatgpt.com<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"

Cardiovascular Disease and Hypertension in Pregnancy \u2013 2025 ESC Guidance Source: 2025 ESC Guidelines on Cardiovascular Disease and Pregnancy; ESC Focused Updates on Hypertension in Pregnancy 1. Shift in Philosophy \u2022 The new 2025 ESC guidelines no longer advise all high-risk women to \u201cavoid pregnancy\u201d categorically. \u2022 Instead, emphasis is on personalized, multidisciplinary care with […]<\/p>\n","protected":false},"author":145,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-8556","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"_links":{"self":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8556","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/users\/145"}],"replies":[{"embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/comments?post=8556"}],"version-history":[{"count":1,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8556\/revisions"}],"predecessor-version":[{"id":8557,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/posts\/8556\/revisions\/8557"}],"wp:attachment":[{"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/media?parent=8556"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/categories?post=8556"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/jordan-cardiac.org\/en\/wp-json\/wp\/v2\/tags?post=8556"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}